ArticleHead & neck2017
Cardiovascular risk and prevention in patients with head and neck cancer treated with radiotherapy.
Article in Head & neck, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Risk of CVD Following Radiotherapy for Head and Neck Cancer: An Updated Systematic Review and Meta-Analysis.Frontiers in oncology · 2022Pooled it
- Cerebrovascular Accident Risk in Survivors of Head and Neck Cancer: JACC CardioOncology State-of-the-Art Review.JACC. CardioOncology · 2026Review
- Cardioprotective medications and the incidence of cardiovascular events in patients treated with radiotherapy: a systematic review and meta-analysis.Cardio-oncology (London, England) · 2026Review
- Risk of cardiovascular disease among head and neck cancer survivors: A population-based matched cohort study.Oral oncology · 2024Article
- Racial and rural-urban disparities in cardiovascular risk factors among patients with head and neck cancer in a clinical cohort.Head & neck · 2022Article
- The risk of cardiovascular disease and stroke in survivors of head and neck cancer in Korea.Health science reports · 2022Article
- Traditional risk factors and cancer-related factors associated with cardiovascular disease risk in head and neck cancer patients.Frontiers in cardiovascular medicine · 2022Article
- Cardiovascular Manifestations From Therapeutic Radiation: A Multidisciplinary Expert Consensus Statement From the International Cardio-Oncology Society.JACC. CardioOncology · 2021Review
- CDK19 as a Potential HPV-Independent Biomarker for Recurrent Disease in HNSCC.International journal of molecular sciences · 2020Article
- Identifying epigenetic biomarkers of established prognostic factors and survival in a clinical cohort of individuals with oropharyngeal cancer.Clinical epigenetics · 2020Article
- Exploratory Review of the Role of Statins, Colchicine, and Aspirin for the Prevention of Radiation-Associated Cardiovascular Disease and Mortality.Journal of the American Heart Association · 2020Review
- Monitoring and Evaluation of Late Functional Outcome in Post-treatment Follow-Up in Clinical Routine Setting.Frontiers in oncology · 2019Review
- Long-term outcome of definitive radiotherapy for cervical esophageal squamous cell carcinoma.Radiation oncology (London, England) · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundThe underlying contributors to cardiovascular disease (CVD) in patients with head and neck squamous cell carcinoma (HNSCC) are poorly characterized.
methodsPatients with HNSCC who underwent definitive or adjuvant (chemo)radiation between 2011 and 2013 were retrospectively reviewed. The 10-year risk estimates for a CVD event were calculated according to the Framingham Risk Score (FRS).
resultsOne hundred fifteen patients with predominantly stage III/IV HNSCC had a median follow-up of 2 years. At diagnosis, 23% of patients had CVD. The FRS was higher among patients with laryngeal cancer versus other sites (20.5% vs 14.4%). Twenty-four percent of all patients had uncontrolled blood pressure at diagnosis. Among the patients with CVD, 41% were not taking antiplatelet therapy and 30% were not taking statin therapy. Thirty-four percent of patients without CVD had indications for initiating statin therapy.
conclusionPatients with HNSCC have a high baseline CVD risk and many do not receive optimal preventive care. © 2016 Wiley Periodicals, Inc. Head Neck 39: 527-532, 2017.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.